Merck Animal Health gets USFDA nod for Bravecto Quantum to protect dogs from fleas, ticks
Rahway: Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, has received approval from the U.S. Food and Drug Administration (FDA) for BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product to treat and protect dogs from fleas and ticks.
The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025.
BRAVECTO QUANTUM was first approved in Australia and New Zealand in 2023, followed by the European Union (EU) in 2024 and now the U.S. in 2025. In total, BRAVECTO QUANTUM is currently approved in more than 50 countries worldwide.
“We take great pride in our company’s leadership in long-acting preventative parasiticides and are excited to offer a convenient option that gives dogs year-round1 comprehensive protection from fleas and ticks in one easy injection they can receive from their veterinarian,” said Christine Royal, DVM, vice president, companion animal and equine business unit, Merck Animal Health. “The approval of BRAVECTO QUANTUM sets a new standard in pet care by providing veterinarians and pet parents with a safe and effective option when it comes to flea and tick protection for dogs.”
BRAVECTO QUANTUM kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and for the treatment and control of tick infestations – Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick) and Rhipicephalus sanguineus (brown dog tick) for 12 months in dogs and puppies 6 months of age and older. BRAVECTO QUANTUM is also indicated for the treatment and control of Amblyomma americanum (lone star tick) infestations for 8 months in dogs and puppies 6 months of age and older.
BRAVECTO QUANTUM is a only parasiticide that protects against fleas and ticks for an entire year with a single dose, offering longer flea and tick protection than any other systemic product currently on the market.
“Though people often think of flea and tick season during the summer months, studies have shown that while fleas and ticks are most active from early spring through the fall, they can be a threat year-round, especially knowing it only takes a few warm days for ticks to become active,” said Frank Guerino, Ph.D., associate vice president of Global Pharmaceutical Development, Merck Animal Health. “With BRAVECTO QUANTUM, a single dose provides year-long, continuous protection, simplifying care for both pet owners and veterinarians, and promoting compliance.”
BRAVECTO QUANTUM utilizes a unique, patented composition of fluralaner that allows effective levels to be maintained for as long as 12 months. Fleas and ticks are a nuisance and pose serious risk to both animal and human health as they can transmit serious diseases. Fleas can also cause severe allergic dermatitis in dogs and cats. Many fleas and ticks can live in both warm and cold temperatures, making continuous year-round protection of utmost importance for pets and people.
